Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Depreciation & Amortization (CF): 2015-2024

Historic Depreciation & Amortization (CF) for UroGen Pharma (URGN) over the last 10 years, with Dec 2024 value amounting to $329,000.

  • UroGen Pharma's Depreciation & Amortization (CF) changed negligibly% to $100,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $329,000, marking a year-over-year decrease of 35.87%. This contributed to the annual value of $329,000 for FY2024, which is 58.98% down from last year.
  • UroGen Pharma's Depreciation & Amortization (CF) amounted to $329,000 in FY2024, which was down 58.98% from $802,000 recorded in FY2023.
  • Over the past 5 years, UroGen Pharma's Depreciation & Amortization (CF) peaked at $924,000 during FY2022, and registered a low of $329,000 during FY2024.
  • Its 3-year average for Depreciation & Amortization (CF) is $685,000, with a median of $802,000 in 2023.
  • In the last 5 years, UroGen Pharma's Depreciation & Amortization (CF) spiked by 99.76% in 2021 and then slumped by 58.98% in 2024.
  • Yearly analysis of 5 years shows UroGen Pharma's Depreciation & Amortization (CF) stood at $416,000 in 2020, then spiked by 99.76% to $831,000 in 2021, then climbed by 11.19% to $924,000 in 2022, then fell by 13.20% to $802,000 in 2023, then plummeted by 58.98% to $329,000 in 2024.